| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05358717 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | PHASE2 | COMPLETED | 159 | — | — | Jun 3, 2022 | Jul 31, 2025 | Jan 13, 2026 | 28 | United States, Australia +9 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.
Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.
| Arm | Type | Description |
|---|---|---|
| PTC518 5 mg | EXPERIMENTAL | Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months. |
| PTC518 10 mg | EXPERIMENTAL | Participants will receive PTC518 10 mg tablets once daily orally for 12 months. |
| PTC518 20 mg | EXPERIMENTAL | Participants will receive PTC518 20 mg tablets once daily orally for 12 months. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months. |
| Name | Type | Description |
|---|---|---|
| PTC518 | DRUG | PTC518 will be administered per dose and schedule specified in the arm. |
| Placebo | DRUG | Placebo matching to PTC518 will be administered per schedule specified in the arm. |
Key Inclusion Criteria: * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length from 40 to 50, inclusive Eligibility for HD-ISS Stage 2 Group (Parts A, B, and C): * A Unified Huntington's Disease Rating Scale (UHDRS)-Independence Scale (IS) score of 100 * A UHDRS ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 2 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |